Oxford brings rare venture capital-backed ABS

Pharma,
By Jennifer Kang
22 Jan 2020

Venture capital firm Oxford Finance is issuing a $312.8m securitization backed by loans made to life sciences and healthcare companies, the largest deal from the issuer and its fastest return to market since issuing its previous deal.

Oxford is a specialty finance company that makes "venture debt" investment in life sciences and healthcare companies with a focus on biotech, pharmaceuticals and medical devices, according to a pre-sale report from Kroll Bond Rating Agency. Since its beginning in 2002, Oxford has originated $5bn loans to more ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial